Mexiletine Shortens the QT Interval in Patients with Potassium Channel-Mediated Type 2 Long QT Syndrome

Keyphrases

• Potassium Channel 100%
• QT Interval 100%
• Long QT Syndrome 100%
• Mexiletine 100%
• LQT2 60%
• Beta-blockers 30%
• Breakthrough Cardiac Events 30%
• LQT3 30%
• Working Diagnosis 20%
• Sodium Channel Blocker 20%
• Visual Overview 20%
• LQT1 20%
• Drug Effects 10%
• Age at Diagnosis 10%
• Therapeutic Efficacy 10%
• Retrospective Chart Review 10%
• Treatment Initiation 10%
• Cardiac Channelopathies 10%
• Pharmacological Targeting 10%
• Sodium Channel 10%
• Corrected QT Interval 10%
• Concomitant Therapy 10%
• 12-lead ECG 10%
• Long QT Syndrome Type 3 10%
• Late Sodium Current 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Potassium Channel 100%
• Mexiletine 100%
• Long QT Syndrome 2 100%
• Long QT Syndrome 3 40%
• Long QT Syndrome 20%
• Long QT Syndrome 1 20%
• Sodium Channel Blocking Agent 20%
• Combination Therapy 10%
• Sodium Channel 10%
• Cardiac Channelopathy 10%